The N-Assay is not yet commercially available. I don't know what steps are needed to take it to market, but I presume that the paper needs to come out if for nothing else than to let the community know what it is, what it can do and offer scientific proof. I would be shocked if publishing of the paper does not generate demand for the product. Whether it does or doesn't, lawyers who represent victims of GBS and other bacteria covered by the paper will help drive the market toward adopting the N-Assay.